Skip Navigation

British National Formulary (BNF) 82

Published jointly by BMJ Publishing Group Ltd and Royal Pharmaceutical Society

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition (BNF 82) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.

Extensive content updates in the BNF 82 edition include:

New monographs for:

  • COVID-19 vaccine for active immunisation against COVID-19 disease
  • Enhertu® [trastuzumab deruxtecan] for HER2-positive unresectable or metastatic breast cancer
  • Myalepta® [metreleptin] for leptin deficiency in lipodystrophy
  • Phesgo® [pertuzumab with trastuzumab] for HER2-positive early-stage, metastatic, or locally recurrent breast cancer
  • Treprostinil for idiopathic or hereditary pulmonary arterial hypertension
  • Trixeo Aerosphere® [formoterol fumarate with glycopyrronium and budesonide] and Bevespi Aerosphere® [glycopyrronium with formoterol fumarate] for chronic obstructive pulmonary disease
  • Von Willebrand Factor for von Willebrand disease

MHRA advice on:

  • Aminoglycosides: increased risk of deafness in patients with mitochondrial mutations
  • Dimethyl fumarate (Tecfidera®): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
  • Epilepsy: updated advice on antiepileptic drugs in pregnancy following comprehensive safety review
  • Erythromycin: caution required due to cardiac risks (QT interval prolongation) and drug interaction with rivaroxaban
  • Fingolimod (Gilenya®): updated advice about the risks of serious liver injury and herpes meningoencephalitis
  • Hydrocortisone (Alkindi®): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules
  • Medicines in pregnancy and breastfeeding: new initiative for consistent guidance and report on optimising data for medicines used during pregnancy
  • Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect when mixed, leading to an increased risk of aspiration
  • Tofacitinib (Xeljanz®▼): initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors
  • Ulipristal acetate 5mg (Esmya®): further restrictions due to risk of serious liver injury
  • SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery

Other significant changes include updated guidance on:

  • COVID-19, including immunisation and recommendations on choice of COVID-19 vaccine in-line with Joint Committee on Vaccination and Immunisation and Public Health England recommendations
  • Management of hypoglycaemia, including age-based dose banding
  • Management of polycystic ovary syndrome
  • National flu immunisation programme and influenza vaccine in-line with Public Health England recommendations
  • Progestogen-only contraceptives in-line with Faculty of Sexual & Reproductive Healthcare recommendations
  • Treatment of human and animal bites
  • Use of hepatitis B immunoglobulin and vaccines in-line with Public Health England recommendations

BNF 82 is an essential publication, it provides you with:

  • Up-to-date information on prescribing, dispensing, and administering medicines
  • Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
  • Information you know you can trust for quality, reliability, and independence
  • Everything you need at your fingertips, all in one book

British National Formulary (BNF) 82

New product




  • ISBN 9780857114136
  • Published Sep 2021
  • Paperback
    210x148x36mm (1880pp)

Other titles to consider...

British National Formulary Joint Formulary Committee

British National Formulary

Joint Formulary Committee

Now available as a 2 year print subscription, ensuring you have the latest medicines information...


RPS Member Price £90.00
Clinical Pharmacist Wright, Matthew

Clinical Pharmacist

Wright, Matthew

Keep abreast of current advances in clinical pharmacy and expand your professional skills and knowledge...


Complementary and Alternative Medicine Kayne, Steven B

Complementary and Alternative Medicine

Kayne, Steven B
Second edition

A practical reference source on alternative and complementary therapies. Enables healthcare professionals to give knowledge-based...


RPS Member Price £32.25

Twitter News@PharmPress

Twitter LinkedIn

Keep in touch

Follow us on LinkedIn and Twitter for the latest updates at Pharmaceutical Press